<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>药物一致性评价 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-26T20:27:45+08:00</updated>
  <subtitle>医药行业</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>科伦药业：唑来膦酸注射液通过仿制药一致性评价</title>
    <updated>2020-11-26T19:16:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/LpDoNBW534Yv26xX1czSKQ</id>
    <link href="https://mp.weixin.qq.com/s/LpDoNBW534Yv26xX1czSKQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>天津力生制药：呋塞米片通过一致性评价</title>
    <updated>2020-11-26T19:16:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/d8MBU0U0w1U6eNNPvIHRiw</id>
    <link href="https://mp.weixin.qq.com/s/d8MBU0U0w1U6eNNPvIHRiw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>石家庄：免费制剂技术会议，你来不来？</title>
    <updated>2020-11-26T19:16:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/uf29LQSWl9r2oN_CbsjGgg</id>
    <link href="https://mp.weixin.qq.com/s/uf29LQSWl9r2oN_CbsjGgg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>资料发补怎么做？CDE发布《药品审评中心补充资料工作程序（试行）》12月1日执行</title>
    <updated>2020-11-25T16:45:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-25:/s/64rWG1X7Jz1h2ITzrs3i-A</id>
    <link href="https://mp.weixin.qq.com/s/64rWG1X7Jz1h2ITzrs3i-A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>扬子江：碘克沙醇注射液重磅过一致性评价，正大天晴该品种在审批！即将集齐3家</title>
    <updated>2020-11-25T16:45:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-25:/s/2ERkFDTf22UBfmSEqF4lEw</id>
    <link href="https://mp.weixin.qq.com/s/2ERkFDTf22UBfmSEqF4lEw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国家局：指导建立粤港澳三地药品监管协作机制</title>
    <updated>2020-11-25T16:45:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-25:/s/l6zr_6R3vdejJUaeAY1UBw</id>
    <link href="https://mp.weixin.qq.com/s/l6zr_6R3vdejJUaeAY1UBw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>NMPA发布第31批+32批参比制剂目录！</title>
    <updated>2020-11-24T09:38:38+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/wHxQqkWju6lrs5_LsqLCcQ</id>
    <link href="https://mp.weixin.qq.com/s/wHxQqkWju6lrs5_LsqLCcQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>毕井泉履新：国经中心常务副理事长</title>
    <updated>2020-11-24T09:38:38+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/L0BGZ1MluBwaYgZtrsJh8g</id>
    <link href="https://mp.weixin.qq.com/s/L0BGZ1MluBwaYgZtrsJh8g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>@医药人，这场石家庄免费制剂技术会议就差你了（内含参会名单）</title>
    <updated>2020-11-24T09:38:38+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/pSobUlMkClvDe-fuYprh1Q</id>
    <link href="https://mp.weixin.qq.com/s/pSobUlMkClvDe-fuYprh1Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CDE发布《化学药品创新药I期临床试验申请药学共性问题相关技术要求》和《化学药品I期临床试验申请药学研究信息汇总表（修订版）》</title>
    <updated>2020-11-23T14:56:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/8ONnVup4xywrqroRjpfetA</id>
    <link href="https://mp.weixin.qq.com/s/8ONnVup4xywrqroRjpfetA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>最新！12个品规通过一致性，4个首家！</title>
    <updated>2020-11-23T14:56:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/CAJmTBibLZFrvWZCdxR8SQ</id>
    <link href="https://mp.weixin.qq.com/s/CAJmTBibLZFrvWZCdxR8SQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>临床期间即可批准上市！CDE发布《药品附条件批准上市技术指导原则（试行）》即日执行</title>
    <updated>2020-11-20T20:07:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/k9BvoN3tCMVcOPQwvmJt5g</id>
    <link href="https://mp.weixin.qq.com/s/k9BvoN3tCMVcOPQwvmJt5g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>7款药物纳入第三批临床急需境外新药名单</title>
    <updated>2020-11-20T20:07:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/tP2-HmKZScAE5xAvHMLALQ</id>
    <link href="https://mp.weixin.qq.com/s/tP2-HmKZScAE5xAvHMLALQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>年销20亿大品种，四川科伦药业注射用帕瑞昔布钠通过仿制药一致性评价</title>
    <updated>2020-11-20T20:07:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/Dtkn6BW7u4d4eltJWm6Kfg</id>
    <link href="https://mp.weixin.qq.com/s/Dtkn6BW7u4d4eltJWm6Kfg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>400亿+贝达药业：1类新药盐酸恩莎替尼胶囊重磅获批</title>
    <updated>2020-11-19T10:37:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-19:/s/Y4wm5CqHwR5l4XzQnTePtw</id>
    <link href="https://mp.weixin.qq.com/s/Y4wm5CqHwR5l4XzQnTePtw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>6个首家，新增9个通过一致性！NMPA 11月19日药品批准证明文件待领取信息发布</title>
    <updated>2020-11-19T10:37:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-19:/s/lhzyiozgbjPi4mW0q3G2xw</id>
    <link href="https://mp.weixin.qq.com/s/lhzyiozgbjPi4mW0q3G2xw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>江西亿友药业吡拉西坦片首家通过一致性评价</title>
    <updated>2020-11-18T17:52:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/bsUdnGIudpRmBFxQPkHEiQ</id>
    <link href="https://mp.weixin.qq.com/s/bsUdnGIudpRmBFxQPkHEiQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>37个一致性产品挂网；21个优先采购品种挂网</title>
    <updated>2020-11-18T17:52:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/VSkGFHwpAtowQD98nRM-6w</id>
    <link href="https://mp.weixin.qq.com/s/VSkGFHwpAtowQD98nRM-6w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【免费】2020“华北地区”药物技术峰会暨仿制药一致性评价大会</title>
    <updated>2020-11-18T17:52:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/0eFSl_N9bIFcWTbqKkiWWA</id>
    <link href="https://mp.weixin.qq.com/s/0eFSl_N9bIFcWTbqKkiWWA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>9个参比制剂未通过审议，CDE《化学仿制药参比制剂目录（第三十五批）》的公示；27新增，15增补</title>
    <updated>2020-11-17T18:39:12+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-17:/s/FLxzkgJuPdjbx_xiGdIoQw</id>
    <link href="https://mp.weixin.qq.com/s/FLxzkgJuPdjbx_xiGdIoQw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>